- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02124265
Oral Rehydration Therapy in Burn Patients (ORT)
Oral Rehydration Therapy in Burn Patients Phase 1
In patients with moderate to severe thermal injuries (> 20% TBSA) adequate fluid resuscitation is the main priority to achieve successful outcomes. Soon after burn injury substantial amounts of fluid accumulate rapidly in the wound while more is lost in the third space. Without intervention this process leads to hypotension and shock. The Parkland formula was devised to calculate how much intravenous (IV) fluid, i.e. crystalloids, is needed for adequate resuscitation during the first 24 hours post-burn. However, IV resuscitation can lead to overexpansion of (third space) volume, leading to severe complications such as compartment syndrome or pulmonary edema.
In major population centers, catastrophic events causing mass casualties will disrupt many hospital and emergency services, potentially delaying acute IV fluid resuscitation. Burn patient case reports have shown that oral rehydration therapy (ORT) used to supplement or in place of IV therapy is efficacious. ORT could be easily applied in mass burn casualties.
ORT is generally known in the third world for treating life-threatening dehydration due to diarrhea. The glucose-sodium co transport mechanism enables the affected human intestine to absorb a sufficient amount of water and electrolytes to replace large fluid losses due to severe diarrhea, even under adverse field conditions. No electrolyte disturbances have been recorded in such cases. Studies on enteral resuscitation in animal burn models showed high rates of small intestinal absorption which should be adequate for resuscitation following major burn injury.
The optimal composition of oral rehydration solution for resuscitation in burn wounds has not been determined. In cholera patients, Ceralyte® has proven superior to the World Health Organization Oral Rehydration Solution, increasing fluid absorption of the intestine. The Ceralyte® 90 solution, with 90mEq/L sodium and a low osmolarity of <275mOsm, may also contribute to optimal intestinal fluid uptake without causing electrolyte disturbances in thermal injury. ORT use might reduce the occurrence of compartment syndrome and pulmonary edema since fluid is regulated by the intestine according to physiologic requirements. The investigators propose to conduct a prospective study using Ceralyte® 90 to show that oral resuscitation therapy (ORT) in burns can reduce the total amount of IV fluid needed for adequate resuscitation and to test the efficacy and safety of ORT in the resuscitation of burn patients.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary objectives
- To show that ORT in burns (using Ceralyte® 90) can reduce the total amount of intravenous fluid needed for adequate resuscitation.
- To test the efficacy and safety of ORT in resuscitation of burn patients Secondary objectives.
- To encourage further research on the use of ORT in large thermal injuries and mass casualty situations.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21224
- Johns Hopkins Bayview Burn Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult patients aged 18-65 years
- Partial- to full-thickness burn injuries involving 20-65% of total body surface area (TBSA)
Exclusion Criteria:
- Presence of inhalation injury
- Hypotension or shock
- Concomitant serious traumatic injury (i.e. head/ spine trauma)
- Gastric Bypass Surgery
- Small Bowel Obstruction
- Delay in resuscitation >2 hrs.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Ceralyte 90
Ceralyte® will be administered during the first 24-hours post-burn.
Fluid requirements will be calculated according to the Parkland Formula with 50% administered during the first 8 hours and the second 50% administered over the next 16 hours.
During the first 2 hours IV fluids will be started at the Parkland goal minus 250cc, which will be administered using Ceralyte via oral, nasogastric (NG), or dobhoff tube.
ORT and IV fluids will be monitored with additional doses given hourly.
Urine output will be monitored hourly and gastric residuals will be monitored every 2 hours, with adjustments made as needed to ensure adequate fluid resuscitation.
|
5. Patients will be monitored according to standard of care. a. If gastric residuals are >300cc, ORT will be stopped and only IV fluid resuscitation will be used. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With a 20% Decrease in Required IV Fluid.
Time Frame: 24 hours post-burn
|
Number of participants whose IV fluids were reduced to less than or equal to 80% of the Parkland Goal IV resuscitation formula within the first 24 hours of initial burn injury. To test the efficacy and safety of Oral RehydrationTherapy in resuscitation of burn patients |
24 hours post-burn
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Stephen M Milner, MBBS, Johns Hopkins University
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 00038778
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fluid Resuscitation
-
Hospital NordRecruitingFluid Responsiveness Predictability | Fluid ResuscitationFrance
-
University of MonastirEnrolling by invitationFluid Therapy | Fluid Resuscitation | Fluid ReponsivenessTunisia
-
Beni-Suef UniversityUnknownFluid Resuscitation Monitoring Non-invasivelyEgypt
-
The George Institute for Global Health, AustraliaCompletedCritical Care, Fluid ResuscitationAustralia
-
McMaster Children's HospitalCompleted
-
Assiut UniversityNot yet recruitingFluid Resuscitation
-
Satu Mare County Emergency HospitalRecruitingFluid Resuscitation | Acute Pancreatitis (AP) | Acute Pancreatic Fluid CollectionRomania
-
McMaster Children's HospitalRegional Medical Associates of HamiltonCompleted
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Medical University of ViennaNot yet recruitingCardiac and Aortic Surgery | Venous Congestion | Fluid Resuscitation | Cardiac Anaesthesia
Clinical Trials on CeraLyte 90
-
GrandPharma (China) Co., Ltd.Enrolling by invitationHepatocellular Carcinoma (HCC) | Hepatocellular Carcinoma Non-ResectableChina
-
M.D. Anderson Cancer CenterSirtex MedicalRecruiting
-
OHSU Knight Cancer InstituteOregon Health and Science University; Boston Scientific CorporationCompleted
-
Massachusetts General HospitalNational Institutes of Health (NIH); Implant SciencesTerminatedSpinal NeoplasmsUnited States
-
Prof. Dr. Cemil Tascıoglu Education and Research...Health Institutes of TurkeyNot yet recruitingNon-Small Cell Lung Cancer | Metastatic Lung CarcinomaTurkey (Türkiye)
-
Emory UniversityNational Cancer Institute (NCI); Sirtex MedicalWithdrawnAnatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma | Metastatic Carcinoma in the LiverUnited States
-
GrandPharma (China) Co., Ltd.Not yet recruiting
-
DaniscoRecruiting
-
Rush University Medical CenterRecruitingRadiculopathy | CRPS (Complex Regional Pain Syndromes) | Peripheral NeuropathyUnited States
-
Sirtex MedicalBright Research PartnersActive, not recruitingUnresectable Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States